“Summary
Omega Pharma NV (Omega Pharma) is a pharmaceutical company. It develops prescription-free health and personal care products. The company’s product portfolio includes cough and cold products, skin care products, pain relief products, vitamins, minerals, and nutritional supplements. Its products cater to gastro-intestinal disorders, respiratory issues, eye care, weight management, food supplements, baby care, and skin care. Besides, the company offers auto-diagnostic products such as body temperature meters, ovulation meters and blood pressure meters. It distributes these products to customers through retail distribution and drug store chains. Perrigo entered into an agreement to acquire Omega Pharma. The company is a subsidiary of Omega Pharma Invest NV. Omega Pharma is headquartered in Nazareth, Belgium
Omega Pharma NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
– Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
– Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
– Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
– Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
– Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
– Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company鈥檚 (major public companies) key financial metrics and ratios.
– Business Description – A brief description of the company’s operations.
– Key Employees – A list of the key executives of the company.
– Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
– Key Competitors – A list of the key competitors of the company.
– Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
– The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
– The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
– Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company鈥檚 operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
– Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
– Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.”
“Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 7
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 9
Omega Pharma NV, Medical Devices Deals, 2009 to YTD 2015 11
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 12
Omega Pharma NV, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 14
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 15
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 16
Omega Pharma Acquires OTC Business from Laboratorios Inibsa 18
Private Equity 19
Waterland Private Equity Investments Acquires Minority Stake In Arseus 19
Partnerships 21
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 21
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 22
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 23
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 24
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 25
Omega Pharma Forms Joint Venture With Modi-Mundipharma 26
Licensing Agreements 27
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27
AVANIR Pharma Terminates Licensing Agreement With ACO HUD 28
Equity Offering 29
Omega Pharma Completes Public Offering Of Shares For US$237 Million 29
Debt Offering 30
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 30
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 32
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 33
Asset Transactions 34
Fareva Acquires Marseille Plant From Omega Pharma 34
Acquisition 35
Perrigo Acquires Omega Pharma for USD4.76 Billion 35
Omega Pharma Acquires Naturoteek 37
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 38
Omega Pharma Acquires Laboratoire de la Mer 40
Omega Pharma Acquires S.C. Hipocrate 2000 42
Omega Pharma NV – Key Competitors 43
Key Employees 44
Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48″
“List of Tables
Omega Pharma NV, Pharmaceuticals & Healthcare, Key Facts 1
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 7
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Omega Pharma NV, Deals By Therapy Area, 2009 to YTD 2015 9
Omega Pharma NV, Medical Devices Deals, 2009 to YTD 2015 11
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 12
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 14
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 15
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 16
Omega Pharma Acquires OTC Business from Laboratorios Inibsa 18
Waterland Private Equity Investments Acquires Minority Stake In Arseus 19
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 21
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 22
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 23
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 24
Meda Enters Into Co-Marketing Agreement With Omega Pharma For SB12 25
Omega Pharma Forms Joint Venture With Modi-Mundipharma 26
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27
AVANIR Pharma Terminates Licensing Agreement With ACO HUD 28
Omega Pharma Completes Public Offering Of Shares For US$237 Million 29
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 30
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 32
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 33
Fareva Acquires Marseille Plant From Omega Pharma 34
Perrigo Acquires Omega Pharma for USD4.76 Billion 35
Omega Pharma Acquires Naturoteek 37
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 38
Omega Pharma Acquires Laboratoire de la Mer 40
Omega Pharma Acquires S.C. Hipocrate 2000 42
Omega Pharma NV, Key Competitors 43
Omega Pharma NV, Key Employees 44
Omega Pharma NV, Subsidiaries 45″
“List of Figures
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 6
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 7
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 8
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 9
Omega Pharma NV, Medical Devices Deals, 2009 to YTD 2015 11″